Together with the previously published findings, the current observations further suggest that molecular inhibitors targeting the PI3K/Akt pathway may improve the outcome by cisplatin-based CCRT in locally advanced cervical cancers harboring PIK3CA mutation. This evidence concerns the gene PIK3CA and cervical carcinoma.